Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA has granted accelerated approval to neladalkib (Nelkarmi), a new oral ALK inhibitor for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). Backed by the phase 1/2 ALKOVE-1 trial, the drug showed meaningful response rates even in heavily pretreated patients — including those with brain metastases. It's a notable development for a patient population that tends to be younger and stays on treatment for years.
The FDA has granted accelerated approval to neladalkib (Nelkarmi), GSK's oral ALK tyrosine kinase inhibitor, for adults with locally advanced or metastatic ALK-positive NSCLC who have already received prior ALK-directed therapy. Specifically, it's approved for patients who received alectinib as their only prior ALK TKI, or those who received two or more prior ALK TKIs plus platinum-based chemotherapy.
The approval was driven by data from the single-arm, open-label phase 1/2 ALKOVE-1 trial. In patients previously treated with alectinib alone, neladalkib achieved a 49% overall response rate (ORR), with over half of responders maintaining their response for at least 12 months. In the more heavily pretreated group, the ORR was 32%, with a median duration of response of 17.3 months — a meaningful result for patients with limited options.
By the Numbers:
Why it matters: ALK-positive NSCLC patients are often younger and can remain on treatment for many years, making durable and tolerable options critical. Neladalkib's activity against ALK resistance mutations — and its intracranial efficacy — fills a real gap for patients who've exhausted earlier-line therapies. A confirmatory phase 3 trial (ALKAZAR) is ongoing.